ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

8296	Companies
114902	Keywords
55328	Articles
62458	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 10/07/2024 at 22:01, 1 month 13 days ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
Abivax congratulates Victor Ambros and Gary Ruvkun on their Nobel Prize for the discovery of microRNA and its role in post-transcriptional gene regulation

Abivax MicroRNA Nobel Prize Victor Ambros Gary Ruvkun
BRIEF

published on 10/03/2024 at 22:06, 1 month 17 days ago

Abivax recruits first patient for its clinical trial on Crohn's disease

Biotechnology Abivax Obefazimod Clinical Trial Crohn's Disease
PRESS RELEASE

published on 10/03/2024 at 22:01, 1 month 17 days ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
Abivax announces enrollment of first patient in Phase 2b trial of Obefazimod for Crohn's Disease, aiming for convenient, effective treatment option with fewer daily burdens

Abivax Obefazimod Phase 2B Trial Immune Response Crohn's Disease
BRIEF

published on 10/03/2024 at 08:35, 1 month 18 days ago

Abivax Announces Positive Results for Obefazimod in Ulcerative Colitis Treatment

Abivax Obefazimod Ulcerative Colitis Clinical Study Safety Analysis
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 month 18 days ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Abivax announces positive interim results of obefazimod in ulcerative colitis patients after 2 years, showing maintenance of remission and safety profile consistency

Abivax Obefazimod Ulcerative Colitis Safety Efficacy
BRIEF

published on 09/26/2024 at 08:35, 1 month 25 days ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Obefazimod Ulcerative Colitis Phase 2b Study UEG Week 2024
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 month 25 days ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax to present Phase 2b trial results of obefazimod in ulcerative colitis at UEG Week 2024, showcasing efficacy and safety data for potential oral therapy

Abivax Obefazimod Ulcerative Colitis Clinical Trial UEG Week 2024
BRIEF

published on 09/25/2024 at 22:06, 1 month 25 days ago

Abivax Announces Ulcerative Colitis Combination Therapy Strategy and Preclinical Data

Obefazimod Ulcerative Colitis Preclinical Data Combination Therapy Etrasimod
PRESS RELEASE

published on 09/25/2024 at 22:01, 1 month 25 days ago

Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
Abivax announces preclinical data of Obefazimod and Etrasimod combination therapy in IBD mouse model, aiming to break through efficacy ceiling in UC treatment. More updates expected in Q4 2024

Abivax Obefazimod Preclinical Data Etrasimod IBD Mouse Model
BRIEF

published on 09/19/2024 at 18:05, 2 months 1 day ago

ABIVAX: Number of shares and voting rights as of August 31, 2024

Euronext Paris Share Capital Voting Rights Biotechnology Abivax

Accesswire

Published on 11/21/2024 at 13:00, 36 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 36 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 36 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 36 minutes ago

Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 36 minutes ago

Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 21 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 1 minute ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 21 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 29 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 36 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 38 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 16 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 51 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 51 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE